Evaluating the QT-Liability of a Drug during its Development

ISSN： 1178-2595

Source： Pharmaceutical Medicine, Vol.22, Iss.3, 2008-01, pp. : 151-164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

hERG-related drug toxicity and models for predicting hERG liability and QT prolongation

By Raschi Emanuel Ceccarini Luisa De Ponti Fabrizio Recanatini Maurizio

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 9, 2009-09 ,pp. : 1005-1021

Informa Healthcare

Access to resources Recommend Favorite

Modelling during drug development

By Balant L.P. Gex-Fabry M.

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 50, Iss. 1, 2000-07 ,pp. : 13-26

Elsevier

Access to resources Recommend Favorite

Antimalarial Drug: From its Development to Deface

Current Drug Discovery Technologies, Vol. 12, Iss. 4, 2015-12 ,pp. : 225-228

Bentham Science Publishers

Access to resources Recommend Favorite

Detection and management of nephrotoxicity during drug development

By Loghman-Adham Dr Mahmoud Kiu Weber Dr Chek Ing Ciorciaro Dr Cornelia Mann Dr Jessica Meier Dr Matthias

Expert Opinion on Drug Safety, Vol. 11, Iss. 4, 2012-07 ,pp. : 581-596

Informa Healthcare

Access to resources Recommend Favorite

Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug Development

By Kuhlmann J. Mück W.

Drug Safety, Vol. 24, Iss. 10, 2001-01 ,pp. : 715-725

Adis International

Access to resources Recommend Favorite